COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,015 Articles (22,627 medRxiv, 8,388 bioRxiv)

Most recent first Previous |  Page 862: Articles 8611-8620  | Next

Modeling within-host and aerosol dynamics of SARS-CoV-2: the relationship with infectiousness
Heitzman-Breen, N., Ciupe, S.
10.1101/2022.03.08.483569 — Posted: 2022-03-09
Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2
Dangi, T., Sanchez, S., Park, M., Class, J., Richner, M. C., Richner, J. M., Penaloza-MacMaster, P.
10.1101/2022.03.09.483635 — Posted: 2022-03-09
Changes in outpatient care patterns and subsequent outcomes during the COVID-19 pandemic: A retrospective cohort analysis from a single payer healthcare system
McAlister, F. A., Hsu, Z., Dong, Y., van Walraven, C., Bakal, J. A.
10.1101/2022.03.07.22272032 — Posted: 2022-03-09
Differential Activity of Repurposed Drugs as Receptor Binding Domain Antagonists for Omicron and Native Strains of SarsCov2
Meher, K., K, S., Reddy, A., Kadiyala, G., Iyer, S., Vangala, S., Chandran, S., Saxena, U.
10.1101/2022.03.09.483630 — Posted: 2022-03-09
Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies
Thuluva, S., Paradkar, V., Turaga, K., Gunneri, S., Yerroju, V., Mogulla, R., Kyasani, M., Manoharan, S., Medigeshi, G. R., Singh, J., Shaman, H., Singh, C., Rao A, V.
10.1101/2022.03.08.22271822 — Posted: 2022-03-09
Culture and identification of a Deltamicron SARS-CoV-2 in a three cases cluster in southern France
Colson, P., Fournier, P.-E., Delerce, J., Million, M., Bedotto, M., Houhamdi, L., Yahi, N., Bayette, J., LEVASSEUR, A., Fantini, J., Raoult, D., LA SCOLA, B.
10.1101/2022.03.03.22271812 — Posted: 2022-03-08
Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine booster
Peng, P., Feng, C., Hu, J., He, C.-l., Deng, H., Fan, Q., Tang, G., Jiang, M., Hu, F., Li, F., Wang, K., Tang, N., Tang, X., Huang, A.
10.1101/2022.03.07.483373 — Posted: 2022-03-08
Hetero-bivalent Nanobodies Provide Broad-spectrum Protection against SARS-CoV-2 Variants of Concern including Omicron
Jin, T., Ma, H., Zhang, X., Zheng, P., Dube, P. H., Zeng, W., Chen, S., Yang, Y., Wu, Y., Zhou, J., Hu, X., Xiang, Y., Zhang, H., Chiu, S.
10.1101/2022.03.08.483381 — Posted: 2022-03-08
Defining factors that influence vaccine-induced, cross-variant neutralizing antibodies for SARS-CoV-2 in Asians
Gu, Y., Shunmuganathan, B. D., Qian, X., Gupta, R., Tan, R. S. W., Kozma, M., Purushotorman, K., Murali, T. M., Tan, N. Y. J., Preiser, P. R., Lescar, J., Nasir, H., Somani, J., Tambyah, P. A., SCOPE Cohort Study Group, , Smith, K. G. C., Renia, L., Ng, L. F. P., Lye, D. C., Young, B. E., MacAry, P. A.
10.1101/2022.03.06.22271809 — Posted: 2022-03-08
13 cis retinoic acid improved the outcomes of COVID-19 patients. A randomized clinical trial
Elkazzaz, M. R., Esam-Eldin Abo-Amer, Y., Ahmed, A., Hayadar, T.
10.1101/2022.03.05.22271959 — Posted: 2022-03-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).